In this issue of Blood, Sallman et al(1) show that myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia (sAML) harboring a TP53 mutation (TP53(mut)) are characterized by immune checkpoint overexpression (programmed death ligand 1 [PD-L1]) at the stem cell level (see figure), which is mediated by dysregulation of the mir-34a/MYC circuit, reduced numbers of cytotoxic T cells, and expansion of myeloid-derived suppressor cells (MDSCs) and ICOShigh/PD-1(neg) regulatory T cells (Tregs). The latter independently correlated with adverse overall survival. The paucity of additional somatic mutations in TP53mut cases was also confirmed in this study, which indicates that this is a distinct molecular entity. MDS/sAML with TP53mut may be enriched with an immunosuppressive profile that could be the primary driver of the rather dismal prognosis found in this molecularly defined subset.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据